Biocytogen (HKEX: 02315) is a pioneering global biotechnology company at the forefront of driving research and development in novel antibody-based drugs through innovative technologies. Founded on cutting-edge gene editing technology, Biocytogen utilizes its genetically engineered proprietary RenMice® platforms (including RenMab™, RenLite®, RenNano®, and RenTCR-mimic™) for the discovery of fully human monoclonal, bispecific, and multispecific antibodies, as well as bispecific antibody-drug conjugates, nanobodies, and TCR-mimic antibodies. The company has also introduced a sub-brand, RenBiologics™, aimed at fostering global partnerships through an off-the-shelf library of over 1,000,000 fully human antibody sequences targeted against more than 1000 specific targets for collaborative projects worldwide. With a robust portfolio of approximately 200 therapeutic antibody and multiple clinical asset co-development agreements, out-licensing arrangements, and transfer agreements, along with over 50 target-nominated RenMice® licensing projects, Biocytogen has solidified its position as an industry leader. Noteworthy collaborations with multinational pharmaceutical companies (MNCs) underscore the company’s commitment to driving innovation and advancing drug discovery. Biocytogen’s groundbreaking work in developing drug target knock-in humanized models for preclinical research has set new standards in the industry. The company offers a diverse range of off-the-shelf animal and cell models under its BioMice™ sub-brand, in addition to providing preclinical pharmacology and gene-editing services to clients globally. Headquartered in Beijing, Biocytogen has strategically located branches in key regions, including China (Haimen Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit the official Biocytogen website.
Tags: biotechnology
Read more from afp.com